arrow
L

Lars Fransecky

universitätsklinikum schleswig holstein
H指数:17
被引数:1,571

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Alterations in 3D-DNA architecture drive unique leukemic profiles in IDH1- and DNMT3A-mutant acute myeloid leukemia

IDH1和DNMT3A突变急性髓系白血病中3D-DNA结构的改变驱动独特的白血病表型

Leukemia
IF13.4
2026-10-010
OAAI
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study

吉列替尼与异基因造血干细胞移植序贯治疗复发/难治FMS样酪氨酸激酶3(FLT3)突变急性髓系白血病患者的多中心真实世界研究

2026-09-050
OAAI
Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemia

异柠檬酸脱氢酶1突变驱动白细胞介素1受体1的下调及急性髓系白血病中失调的炎症反应

2026-01-060
OAAI
Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy
2026-01-010
OAAI
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

阿扎胞苷治疗具有可测量残留病灶的患者中的骨髓增生异常综合征/急性髓系白血病:RELAZA2试验的最终长期结果

Blood
IF23.1
2025-12-100
PRE
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients

4978例接受强化治疗的AML欧洲患者队列中,髓系发育异常相关基因突变的不同预后影响

Leukemia
IF13.4
2025-10-270
OA
Epidemiology, survival, and treatment of acute myeloid and lymphoblastic leukaemia in Germany: a nationwide population-based registry analysis

流行病学、生存率及急性髓系和淋巴母细胞白血病的治疗:德国一项基于全国人口登记库的分析

2025-10-180
OAAI
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis

吉姆单抗奥佐米星在CBF-AML一线治疗中的应用:一项回顾性多中心分析的见解

Leukemia
IF13.4
2025-07-210
OA
Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment

CPX-351在急性髓系白血病中的诱导化疗:重新评估早期骨髓评估的作用

Leukemia
IF13.4
2025-07-030
OAAI
Proteomic profiling reveals ACSS2 facilitating metabolic support in acute myeloid leukemia
2024-06-082
OAAI
Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols
LEUKEMIA
IF13.4
2024-05-140
OAAI
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens
2024-04-241
OAAI
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European leukemia net risk classification
LEUKEMIA
IF13.4
2023-09-0711
OAAI
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience
2023-08-042
OA
Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial

NPM1-mutated急性髓系白血病患者接受或不接受吉妥珠单抗ozogamicin的强化化疗 (AMLSG 09-09): 一项随机、开放标签、多中心、3期试验

2023-07-0131
PRE